Overview

RICE: Remission by Intra-articular Injection Plus CErtolizumab

Status:
Completed
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
Tight control of an adaptive concomitant treatment strategy after initiation of CZP will lead to an improved outcome of RA patients with an active disease despite DMARD treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Rüdiger B. Müller
Collaborator:
UCB Pharma
Treatments:
Certolizumab Pegol
Glucocorticoids
Sulfasalazine